此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

弥漫性大B细胞淋巴瘤一线化学免疫治疗期间的MRD适应性低剂量放射治疗 (MRD-XRT)

2026年11月4日 更新者:University of Nebraska

弥漫性大B细胞淋巴瘤中MRD适应性周期中低剂量放疗联合一线R-化学免疫疗法的可行性研究(MRD XRT)

This prospective Phase IIA feasibility study evaluates a minimal residual disease (MRD)-adapted treatment strategy in patients with diffuse large B-cell lymphoma (DLBCL) receiving frontline R-chemoimmunotherapy. Circulating tumor DNA (ctDNA)-based MRD testing and interim positron emission tomography (PET) imaging after two cycles of therapy are used to guide treatment decisions. Patients with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard systemic therapy. Patients with undetectable MRD, or detectable MRD without targetable residual disease, continue standard frontline chemoimmunotherapy without protocol-directed LDRT.

研究概览

详细说明

Diffuse large B-cell lymphoma (DLBCL) is commonly treated with frontline R-chemoimmunotherapy regimens such as R-CHOP or related combinations. Interim positron emission tomography (PET) imaging provides information about treatment response, while circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing allows assessment of molecular residual disease during treatment.

This prospective, non-randomized Phase IIA feasibility study evaluates the integration of ctDNA-based MRD testing and interim PET imaging into frontline treatment decisions for patients with DLBCL. Approximately 50 participants are expected to enroll.

Following two cycles of frontline R-chemoimmunotherapy, participants undergo protocol-specified MRD testing and interim PET assessment. Participants with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy are assigned to Arm A and receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard frontline chemoimmunotherapy.

Participants with undetectable MRD, as well as those with detectable MRD but without targetable residual disease, are assigned to Arm B and continue standard frontline chemoimmunotherapy without protocol-directed LDRT.

The primary objective is to evaluate the feasibility of this MRD-adapted strategy, including successful completion of MRD testing after cycle 2 and delivery of protocol-directed LDRT to eligible MRD-positive participants. Secondary assessments include treatment response, progression-free survival, overall survival, the impact of LDRT on systemic treatment delivery, and patient-reported quality of life.

研究类型

介入性

注册 (估计的)

50

阶段

  • 阶段2

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

  • 姓名:IIT Office Clinical Trails Office
  • 电话号码:(402) 5590963
  • 邮箱:IITOFFICE@unmc.edu

学习地点

    • Nebraska
      • Omaha、Nebraska、美国、68198
        • Fred & Pamela Buffet Cancer Center
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

19年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Adults ≥19 years of age
  2. Biopsy-proven newly diagnosed DLBCL, transformed from indolent lymphoma, Follicular lymphoma grade 3B, post-transplant lymphoproliferative disorder, or any other subtypes of Large B-cell lymphoma under WHO-HAEM5 classification who are eligible and plan to receive 6 cycles of R-chemoimmunotherapy. Note: patients may receive up to one cycle of R-chemoimmunotherapy prior to enrollment.
  3. Planned to receive 6 cycles of frontline R-chemoimmunotherapy for diseases mentioned in criterion 2
  4. Presence of measurable disease on imaging, nodal lesion >1.5cm or extra-nodal lesion >1 cm prior to initiation of R-chemoimmunotherapy
  5. Availability of sufficient and viable baseline FFPE tumor tissue to allow development of a personalized MRD assay

Exclusion Criteria:

  1. Limited stage (Ann Arbor stage I-II) DLBCL, requiring less than 6 cycles of R-chemoimmunotherapy
  2. Primary or secondary CNS lymphoma
  3. Subject has exceeded maximum lifelong cumulative doses of radiation therapy or is unsafe for radiation therapy as determined by the investigator and/or radiation oncologist
  4. Pregnant and lactating patients
  5. Has received two or more cycles of R-chemoimmunotherapy relating to this disease

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Arm- A: MRD-Detectable with Protocol-Directed LDRT

Participants with detectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) to targetable residual disease sites in addition to standard frontline chemoimmunotherapy.

Low-dose radiation therapy delivered to residual PET-avid disease sites identified after interim assessment with PET imaging and MRD testing.

Standard-of-care frontline chemoimmunotherapy regimens for diffuse large B-cell lymphoma, including R-CHOP, Pola-R-CHP, DA-EPOCH-R, R-CEOP, or related regimens as determined by the treating physician.

有源比较器:Arm B: Standard Therapy Without Protocol-Directed LDRT

Participants with undetectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy, or participants with detectable MRD but without residual PET-avid or measurable disease suitable for radiation therapy, continue standard frontline chemoimmunotherapy without protocol-directed low-dose radiation therapy (LDRT).

Standard-of-care frontline chemoimmunotherapy regimens for diffuse large B-cell lymphoma, including R-CHOP, Pola-R-CHP, DA-EPOCH-R, R-CEOP, or related regimens as determined by the treating physician.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Feasibility of Real-Time MRD-Guided Treatment Strategy
大体时间:From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).

Feasibility will be assessed by the proportion of enrolled patients who successfully complete protocol-specified MRD testing after two cycles of chemoimmunotherapy and, among patients with detectable MRD, the proportion who successfully receive protocol-defined low-dose radiation therapy (LDRT). Feasibility will be considered acceptable if at least 80% of enrolled patients complete MRD testing and at least 80% of ctDNA-positive patients receive LDRT.

From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).

次要结果测量

结果测量
措施说明
大体时间
Overall response rate (ORR), Including Complete Response (CR) and Partial Response (PR) Rates
大体时间:At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).

The proportion of participants achieving complete response (CR) or partial response (PR), with complete response rate assessed separately. Response will be evaluated using PET/CT imaging according to Lugano 2014 criteria.

At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
Progression-Free Survival (PFS)
大体时间:From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.

Progression-free survival is defined as the time from initiation of frontline therapy until disease progression or death from any cause. PFS will be estimated using the Kaplan-Meier method.

From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.
Overall Survival (OS)
大体时间:From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.

Overall survival is defined as the time from initiation of frontline therapy until death from any cause. OS will be estimated using the Kaplan-Meier method.

From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.
Impact of Low-Dose Radiation Therapy on Delivery of Systemic Chemoimmunotherapy
大体时间:From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).

The impact of protocol-directed low-dose radiation therapy (LDRT) on the delivery of planned systemic chemoimmunotherapy will be assessed by treatment delays, dose reductions, omitted chemotherapy cycles, or premature discontinuation of systemic therapy attributable to LDRT.

From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
大体时间:At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).

Patient-reported quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), evaluating global health status, functional domains, and symptoms.

At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Snegha Ananth, MBBS、University of Nebraska

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年12月12日

初级完成 (估计的)

2031年2月12日

研究完成 (估计的)

2033年2月12日

研究注册日期

首次提交

2026年3月24日

首先提交符合 QC 标准的

2026年4月3日

首次发布 (实际的)

2026年4月8日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月4日

最后验证

2026年11月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅